ABBVAbbVieSigning up patients
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non Small Cell Lung Carcinoma · c-MET
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 252 (planned)
- Started
- Mar 6, 2025
- Main results expected
- Nov 2027
- Fully finished
- Nov 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan
Measured over: Up to Approximately 84 Days
Part 2: Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to Approximately 33 Months
Number of Participants with Adverse Events (AE)s
Measured over: Up to Approximately 33 Months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06772623 · record last updated 2026-10-27 · checked 2026-11-09 15:47 UTC